Commercial rights to ATI-1501 for Europe, Latin America and the United States markets have been licensed to Saptalis Pharmaceuticals, a R&D-driven pharmaceutical company focused on development and commercialization of complex niche products including oral suspensions. Appili retains global rights to ATI-1501 outside the United States, which are available for licensing. Learn more about ATI-1501 below.
1) The resuspension process often incurs additional costs and increases the potential for dosing errors.
2) Critically, it is also ineffective at taste masking; metronidazole crushed and resuspended in food remains among the worst tasting antibiotics on market.
“For far too long, the bitter taste of the current form of metronidazole has made it challenging for patients to take, increasing rates of treatment failure, infection recurrence and antibiotic resistance. This patent protects our investment in making metronidazole more accessible and easier to take for all patients, especially for the elderly and children who often have difficulty taking solid oral medicines.”
–Appili President and CEO, Don Cilla, PharmD, MBA
Appili announced that the United States Patent and Trademark Office has issued a Notice of Allowance of new patent claims for ATI-1501. A notice of allowance is issued by the USPTO to indicate that the application has passed the examination.
Appili and their partner Saptalis Pharmaceuticals expect ATI-1501 to be approved by the FDA by the end of 2023.
Ben Salah A 2013 N Engl J Med 368: 524-532
Prescribing for children – taste and palatability affect adherence to antibiotics: a review.
Hoppe (1996) Pharmacoeconomics:
Boateng (2017) J Pharm Sci: